Literature DB >> 8136267

Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome.

T Nakagawa1, S Matozaki, T Murayama, R Nishimura, M Tsutsumi, R Kawaguchi, Y Yokoyama, K Hikiji, T Isobe, K Chihara.   

Abstract

A cell line designated SKM-1 was newly established from leukaemic cells of a 76-year-old Japanese male patient with monoblastic leukaemia following myelodysplastic syndrome (MDS). The cells were obtained from peripheral blood of the patient when he lost multiple point mutations of ras genes with acquisition of chromosomal abnormalities during disease progression in MDS. The cells grew as a single floating cell, and have been continuously growing with the morphological characteristics of immature monoblasts by serial passages during the past 42 months with a doubling time of about 48 h. By cytochemical analysis, the cloned cells were positive for butyrate esterase, but negative for the Epstein-Barr virus associated nuclear antigen. Phenotypic analysis revealed the expression of myelomonocyte specific antigens such as CD4, CD13, CD33 and HLA-DR. Cells from the primary peripheral blood and those from 50 passages of the SKM-1 cell line both possessed no activated ras genes but showed karyotype abnormalities with 46,XY, del(9)(q13;q22), der(17) t(17;?)(p13;?). The SKM-1 cells have two mutations in p53 gene and overexpress the p53 products. This cell line may contribute to a better understanding of molecular mechanisms in the progression from MDS to myelogenous leukaemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8136267     DOI: 10.1111/j.1365-2141.1993.tb03334.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  23 in total

1.  Chidamide shows synergistic cytotoxicity with cytarabine via inducing G0/G1 arrest and apoptosis in myelodysplastic syndromes.

Authors:  Zhaoyun Liu; Jin Chen; Honglei Wang; Kai Ding; Yanqi Li; Anya de Silva; Varun Sehgal; Jonathan Lvan Burbano; Radhika Sundararaj; Janani Gamage; Victor Audu; Rong Fu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  The effect of sodium butyrate in combination with ATRA on the proliferation/differentiation of SKM-1.

Authors:  Mei Huang; Wenli Liu; Chunrui Li; Jinniu Deng; Jianfeng Zhou; Donghua Zhang; Hanying Sun
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

3.  Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.

Authors:  Pingyan Cheng; Xianghong Chen; Robert Dalton; Alexandra Calescibetta; Tina So; Danielle Gilvary; Grace Ward; Victoria Smith; Sterling Eckard; Judith A Fox; Jeanmarie Guenot; Joseph Markowitz; John L Cleveland; Kenneth L Wright; Alan F List; Sheng Wei; Erika A Eksioglu
Journal:  Mol Ther       Date:  2022-02-09       Impact factor: 12.910

4.  Effect of magnetic Fe3O4 nanoparticles with 2-methoxyestradiol on the cell-cycle progression and apoptosis of myelodysplastic syndrome cells.

Authors:  Guohua Xia; Baoan Chen; Jiahua Ding; Chong Gao; Huixia Lu; Zeye Shao; Feng Gao; Xuemei Wang
Journal:  Int J Nanomedicine       Date:  2011-09-08

5.  Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.

Authors:  Yingxing Yue; Ying Wang; Yang He; Shuting Yang; Zixing Chen; Yuanyuan Wang; Shanshan Xing; Congcong Shen; Hesham M Amin; Depei Wu; Yao-Hua Song
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

6.  Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome.

Authors:  Jixue Zou; Yan Hong; Yin Tong; Ju Wei; Youwen Qin; Shan Shao; Chun Wang; Kun Zhou
Journal:  Stem Cells Int       Date:  2015-03-15       Impact factor: 5.443

7.  Downregulation of hTERT: an important As2O3 induced mechanism of apoptosis in myelodysplastic syndrome.

Authors:  Weilai Xu; Yungui Wang; Hongyan Tong; Wenbin Qian; Jie Jin
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

8.  SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.

Authors:  Bing-Yi Chen; Junhong Song; Cheng-Long Hu; Shu-Bei Chen; Qunling Zhang; Chun-Hui Xu; Ji-Chuan Wu; Dan Hou; Ming Sun; Yuan-Liang Zhang; Na Liu; Peng-Cheng Yu; Ping Liu; Li-Juan Zong; Jia-Ying Zhang; Ruo-Fei Dai; Fei Lan; Qiu-Hua Huang; Su-Jiang Zhang; Stephen D Nimer; Zhu Chen; Sai-Juan Chen; Xiao-Jian Sun; Lan Wang
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

9.  Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and gene-bodies.

Authors:  Yan-Fung Wong; Lars Martin Jakt; Shin-Ichi Nishikawa
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

10.  SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.

Authors:  Qing Nian; Qing Xiao; Li Wang; Jing Luo; Li-Ping Chen; Ze-Song Yang; Lin Liu
Journal:  Int J Mol Med       Date:  2014-02-07       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.